• Record: found
  • Abstract: found
  • Article: found
Is Open Access

Brexit – What are the potential consequences for pharma patents and SPCs?


British Journal of Pharmacy

University of Huddersfield Press

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Brexit raises a number of difficult questions with regard to intellectual property rights in a post-Brexit world, particularly for UK based pharma companies. Whilst the position with regard to the current European patent system is unchanged, the fate of the unitary patent and the unified patent court remains uncertain. Of more immediate concern is the possible future position with respect to supplementary patent certificates. Should the UK fail to reach an agreement with the EU with respect to marketing authorisations for new pharmaceuticals then there is a real possibility that UK based pharma companies may find themselves in a position where they are unable to obtain EU-wide SPC protection.

      Related collections

      Author and article information

      British Journal of Pharmacy
      University of Huddersfield Press
      September 05 2017
      September 05 2017
      : 2
      : 1
      © 2017

      This work is licensed under a Creative Commons Attribution 4.0 Unported License. To view a copy of this license, visit



      Comment on this article